June 4, 2010 / 5:21 AM / 9 years ago

Novartis' Tasigna better than Glivec in leukemia

ZURICH, June 4 (Reuters) - Swiss drug-maker Novartis NOVN.VX said its Tasigna cancer drug proved more efficient in slowing down chronic myeloid leukemia (CLM) in 18-month results than its older medicine Glivec.

A previous study had shown Tasigna exceeded Novartis’ Glivec in disease progression over 12 months.

Novartis is relying on Tasigna to replace sales of Glivec, which is its second biggest seller but loses patent protection over the next few years.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below